# US 2023/0255970 A1 · Compositions and methods for treating proliferative diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0255970 A1
- Document ID: US20230255970A1
- Status: Published application
- Kind: A1
- Application number: 18/020,827
- Filed: 2021-08-12
- Published: 2023-08-17
- Earliest claimed: 2020-08-12
- Assignees: The Broad Institute, Inc.; The Trustees of the University of Pennsylvania
- Applicants: The Broad Institute, Inc.; The Trustees of the University of Pennsylvania
- Inventors: Tzipora Sarah Karin EISINGER; Gabrielle CIOTTI; Ashley M. FULLER; Mohammad ROHBAN; Anne Carpenter VAN DYK; Shantanu SINGH
- Web page: https://patentgrep.com/patent/US20230255970A1

## CPC

- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/03: aromatic
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/415: 1,2-Diazoles
- A61K 31/4192: 1,2,3-Triazoles
- A61K 31/43: Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula [IMAGE cpc-sch-A61K-0952.gif], e.g. penicillins, penems
- A61K 31/438: The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A61K 31/4402: only substituted in position 2, e.g. pheniramine, bisacodyl
- A61K 31/4409: only substituted in position 4, e.g. isoniazid, iproniazid
- A61K 31/4433: containing a six-membered ring with oxygen as a ring hetero atom
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 31/5513: 1,4-Benzodiazepines, e.g. diazepam {or clozapine}
- A61P 35/00: Antineoplastic agents
- C07D 209/52: condensed with a ring other than six-membered
- C07D 213/75: Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- C07D 243/10: condensed with carbocyclic rings or ring systems
- C07D 267/00: Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 419/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 498/04: Ortho-condensed systems
- C07D 498/08: Bridged systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention features compositions and methods for treating proliferative diseases such as cancer (e.g., sarcoma, pancreas, prostate, head and neck, liver, and breast cancer) that inhibit the growth of NF-κB and/or Hippo associated neoplasias.

## Claims

### Claim 1

A method for inhibiting proliferation or survival of a neoplasia associated with an NF-κB pathway in a cell, the method comprising contacting the cell with a compound selected from the group consisting of:
N-[[(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14 tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methyl-4 phenoxybenzenesulfonamide,
(4S,5R)-5-((dimethylamino)methyl)-2-((R)-1-hydroxypropan-2-yl)-4-methyl-8-(pyridin-2-ylethynyl)-2,3,4,5-tetrahydrobenzo[b][1,4,5]oxathiazocine 1,1-dioxide,
N-[(4S,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-15-yl]-4-phenylbenzamide,
1-[(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-[4-(trifluoromethyl)phenyl]urea,
2-[(3 S,6aR,8S,10aR)-3-hydroxy-1-(3-methoxyphenyl)sulfonyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-(4-phenyl-1-piperazinyl)ethanone, 1-pyridin-4-yl-3-(2,4,6-trichlorophenyl)urea,
4-(5,7,7,10,10-pentamethyl-8,9-dihydronaphtho[2,3-b][1,4]benzodiazepin-13-yl)benzoic acid (LE-135),
1-(3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl)-3-(4-methylphenyl)sulfonylurea,
5-(1,4-diazepan-1-ylsulfonyl)-2H-isoquinolin-1-one,
1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline,
5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine,
7-hydroxy-3-(4-hydroxyphenyl)chromen-4-one,
N-benzylquinazolin-4-amine,
(2R,3R,3aS,9bS)-7-(1-cyclohexenyl)-N-(cyclopropylmethyl)-3-(hydroxymethyl)-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide,
N-[(1R,3R,4aS,9aR)-3-[2-[(3-fluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide,
(1S,9R,10R,11R)-11-N-ethyl-10-(hydroxymethyl)-5-(2-methoxyphenyl)-6-oxo-12-N-propyl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11,12-dicarboxamide,
N-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(1-piperidinyl)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-4-oxanecarboxamide,
N-[(5S,6S,9S)-8-(cyclopropylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-fluorobenzamide,
N-[(4R,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(1,3-thiazol-2-ylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide,
2-[(3 S,6aR,8R,10aR)-1-(1,3-benzodioxol-5-ylmethyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-piperidin-1-ylethanone,
2-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-6-[(3-methoxyphenyl)sulfonylamino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester,
4-fluoro-N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]benzenesulfonamide,
N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1,3-thiazol-2-ylamino)ethyl]oxan-3-yl]-3-piperidin-1-ylpropanamide,
N-[(4S,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(phenylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide,
2-[(2R,3R,6S)-3-[[(2,5-difluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[3-(4-morpholinyl)propyl]acetamide,
N-benzyl-2-chloroquinazolin-4-amine,
N-[(2R,3 S,6S)-6-[2-[(4-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)oxan-3-yl]oxane-4-carboxamide,
5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-(trifluoromethane)sulfinyl-1H-pyrazole-3-carbonitrile,
N-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(pyridin-2-ylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]cyclobutanecarboxamide, and
and 1-[[(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-1-methyl-3-(3-pyridin-2-yloxyphenyl)urea; or
a pharmaceutically acceptable salt thereof, or a tautomer, stereoisomer, prodrug and/or solvate of any of the foregoing;
thereby inhibiting proliferation or survival of the cell.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound is selected from the group consisting of N-benzylquinazolin-4-amine,
N-[(4S,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-15-yl]-4-phenylbenzamide, and
1-[(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-[4-(trifluoromethyl)phenyl]urea; or
a pharmaceutically acceptable salt thereof, or a tautomer, stereoisomer, prodrug and/or solvate of any of the foregoing.

### Claim 3 (depends on 2)

The method of claim 2, wherein the cell is contacted with an effective amount of N-benzylquinazolin-4-amine; or
a pharmaceutically acceptable salt thereof, or a tautomer, stereoisomer, prodrug and/or solvate of any of the foregoing.

### Claim 4 (depends on 1)

The method of claim 1, wherein the neoplasia is selected from the group consisting of sarcoma, pancreatic cancer, prostate cancer, head and neck cancer, breast cancer, and liver cancer.

### Claim 5 (depends on 1)

The method of claim 1, wherein the cell is a mammalian cell.

### Claim 6 (depends on 1)

The method of claim 1, wherein the cell is in vitro or in vivo.

### Claim 7

A method for inhibiting proliferation or survival of a neoplasia associated with a Hippo pathway in a cell, the method comprising contacting the cell with a compound selected from the group consisting of:
N-[[(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14 tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methyl-4 phenoxybenzenesulfonamide,
(4S,5R)-5-((dimethylamino)methyl)-2-((R)-1-hydroxypropan-2-yl)-4-methyl-8-(pyridin-2-ylethynyl)-2,3,4,5-tetrahydrobenzo[b][1,4,5]oxathiazocine 1,1-dioxide,
N-[(4S,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-15-yl]-4-phenylbenzamide,
1-[(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-[4-(trifluoromethyl)phenyl]urea,
2-[(3 S,6aR,8S,10aR)-3-hydroxy-1-(3-methoxyphenyl)sulfonyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-(4-phenyl-1-piperazinyl)ethanone, 1-pyridin-4-yl-3-(2,4,6-trichlorophenyl)urea,
4-(5,7,7,10,10-pentamethyl-8,9-dihydronaphtho[2,3-b][1,4]benzodiazepin-13-yl)benzoic acid (LE-135),
1-(3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl)-3-(4-methylphenyl)sulfonylurea,
5-(1,4-diazepan-1-ylsulfonyl)-2H-isoquinolin-1-one,
1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline,
5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine,
7-hydroxy-3-(4-hydroxyphenyl)chromen-4-one,
N-benzylquinazolin-4-amine,
(2R,3R,3aS,9bS)-7-(1-cyclohexenyl)-N-(cyclopropylmethyl)-3-(hydroxymethyl)-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide,
N-[(1R,3R,4aS,9aR)-3-[2-[(3-fluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide,
(1S,9R,10R,11R)-11-N-ethyl-IO-(hydroxymethyl)-5-(2-methoxyphenyl)-6-oxo-12-N-propyl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11,12-dicarboxamide,
N-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(1-piperidinyl)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-4-oxanecarboxamide,
N-[(5S,6S,9S)-8-(cyclopropylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-fluorobenzamide,
N-[(4R,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(1,3-thiazol-2-ylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide,
2-[(3 S,6aR,8R,10aR)-1-(1,3-benzodioxol-5-ylmethyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-piperidin-1-ylethanone,
2-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-6-[(3-methoxyphenyl)sulfonylamino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester,
4-fluoro-N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]benzenesulfonamide,
N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1,3-thiazol-2-ylamino)ethyl]oxan-3-yl]-3-piperidin-1-ylpropanamide,
N-[(4S,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(phenylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide,
2-[(2R,3R,6S)-3-[[(2,5-difluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[3-(4-morpholinyl)propyl]acetamide,
N-benzyl-2-chloroquinazolin-4-amine,
N-[(2R,3 S,6S)-6-[2-[(4-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)oxan-3-yl]oxane-4-carboxamide,
5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-(trifluoromethane)sulfinyl-1H-pyrazole-3-carbonitrile,
N-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(pyridin-2-ylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]cyclobutanecarboxamide, and
1-[[(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-1-methyl-3-(3-pyridin-2-yloxyphenyl)urea; or
a pharmaceutically acceptable salt thereof, or a tautomer, stereoisomer, prodrug and/or solvate of any of the foregoing;
thereby inhibiting proliferation or survival of the cell.

### Claim 8 (depends on 7)

The A-method of claim 7, wherein the compound is selected from the group consisting of N-benzylquinazolin-4-amine,
N-[(4S,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-15-yl]-4-phenylbenzamide, and
1-[(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-[4-(trifluoromethyl)phenyl]urea; or
a pharmaceutically acceptable salt thereof, or a tautomer, stereoisomer, prodrug and/or solvate of any of the foregoing.

### Claim 9 (depends on 8)

The method of claim 8, wherein the cell is contacted with an effective amount of N-benzylquinazolin-4-amine; or
a pharmaceutically acceptable salt thereof, or a tautomer, stereoisomer, prodrug and/or solvate of any of the foregoing.

### Claim 10 (depends on 7)

The method of claim 7, wherein the neoplasia is selected from the group consisting of sarcoma, pancreatic cancer, prostate cancer, head and neck cancer, breast cancer, and liver cancer.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the neoplasia is undifferentiated pleomorphic sarcoma.

### Claim 12 (depends on 7)

The method of claim 7, wherein the cell is a mammalian cell.

### Claim 13 (depends on 7)

The method of claim 7, wherein the cell is in vitro or in vivo.

### Claim 14

A method of treating a neoplasia associated with the NF-κB and/or Hippo pathway in a subject, the method comprising administering to the subject a compound selected from the group consisting of:
(1S,9R,10R,11R)-11-N-ethyl-10-(hydroxymethyl)-5-(2-methoxyphenyl)-6-oxo-12-N-propyl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11,12-dicarboxamide,
(2R,3R,3aS,9bS)-7-(1-cyclohexenyl)-N-(cyclopropylmethyl)-3-(hydroxymethyl)-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide,
(4S,5R)-5-((dimethylamino)methyl)-2-((R)-1-hydroxypropan-2-yl)-4-methyl-8-(pyridin-2-ylethynyl)-2,3,4,5-tetrahydrobenzo[b][1,4,5]oxathiazocine 1,1-dioxide,
1-(3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl)-3-(4-methylphenyl)sulfonylurea,
1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline,
1-[(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-[4-(trifluoromethyl)phenyl]urea,
1-[[(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-1-methyl-3-(3-pyridin-2-yloxyphenyl)urea,
2-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-6-[(3-methoxyphenyl)sulfonylamino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester,
2-[(2R,3R,6S)-3-[[(2,5-difluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[3-(4-morpholinyl)propyl]acetamide,
2-[(3 S,6aR,8R,10aR)-1-(1,3-benzodioxol-5-ylmethyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-piperidin-1-ylethanone,
2-[(3 S,6aR,8S,10aR)-3-hydroxy-1-(3-methoxyphenyl)sulfonyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-(4-phenyl-1-piperazinyl)ethanone1-pyridin-4-yl-3-(2,4,6-trichlorophenyl)urea,
4-(5,7,7,10,10-pentamethyl-8,9-dihydronaphtho[2,3-b][1,4]benzodiazepin-13-yl)benzoic acid (LE-135),
4-fluoro-N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]benzenesulfonamide,
5-(1,4-diazepan-1-ylsulfonyl)-2H-isoquinolin-1-one,
5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine,
5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-(trifluoromethane)sulfinyl-1H-pyrazole-3-carbonitrile,
7-hydroxy-3-(4-hydroxyphenyl)chromen-4-one,
N-[(1R,3R,4aS,9aR)-3-[2-[(3-fluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide,
N-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(1-piperidinyl)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-4-oxanecarboxamide,
N-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(pyridin-2-ylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]cyclobutanecarboxamide,
N-[(2R,3 S,6S)-6-[2-[(4-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)oxan-3-yl]oxane-4-carboxamide,
N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1,3-thiazol-2-ylamino)ethyl]oxan-3-yl]-3-piperidin-1-ylpropanamide,
N-[(4R,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(1,3-thiazol-2-ylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide,
N-[(4S,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(phenylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide,
N-[(4S,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-15-yl]-4-phenylbenzamide,
N-[(5S,6S,9S)-8-(cyclopropylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-fluorobenzamide,
N-[[(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14 tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methyl-4 phenoxybenzenesulfonamide,
N-benzyl-2-chloroquinazolin-4-amine, and
N-benzylquinazolin-4-amine; or
a pharmaceutically acceptable salt thereof, or a tautomer, stereoisomer, prodrug and/or solvate of any of the foregoing.

### Claim 15 (depends on 14)

The method of claim 14, wherein the is selected from the group consisting of N-benzylquinazolin-4-amine, N-[(4S,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-15-yl]-4-phenylbenzamide, and 1-[(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-[4-(trifluoromethyl)phenyl]urea; or
a pharmaceutically acceptable salt thereof, or a tautomer, stereoisomer, prodrug and/or solvate of any of the foregoing.

### Claim 16 (depends on 15)

The method of claim 15, the method comprising administering to the subject N-benzylquinazolin-4-amine.

### Claim 17 (depends on 14)

The method of claim 14, wherein the neoplasia is selected from the group consisting of sarcoma, bladder cancer, pancreatic cancer, prostate cancer, head and neck cancer, breast cancer, and liver cancer.

### Claim 18 (depends on 17)

The method of claim 17, wherein the neoplasia is undifferentiated pleomorphic sarcoma.

### Claim 19 (depends on 14)

The method of claim 14, wherein said neoplasia is associated with the NF-κB pathway.

### Claim 20 (depends on 14)

The method of claim 14, wherein said neoplasia is associated with the Hippo pathway.
